StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Adcetris (brentuximab vedotin ADC by Year

Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Adcetris (brentuximab vedotin ADC: $907M in FY2025, down 16.7% from a year earlier.

Latest, FY2025
907
Period ended Dec 31, 2025
Change on a year earlier
-16.7%
1,089 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Adcetris (h) | 907 | 1,089 | (17%) | (17%) | 885 | 1,059 | (16%) | 23 | 30 | (25%) | (23%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 2025907-16.7%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 20241,089+1,844.6%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 202356–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20220–Form 10-K (filed 2025-02-27) ↗
FY2021Dec 31, 20210–Form 10-K (filed 2024-02-22) ↗

Breakdown

What makes up adcetris (brentuximab vedotin ADC

Cite this data

StockData. (2026). Pfizer Adcetris (brentuximab vedotin ADC ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/adcetris-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.